By RJ Vogt ( August 21, 2018, 9:31 PM EDT) -- The First Circuit on Tuesday granted Novartis' bid to dismiss an antitrust suit alleging it used sham litigation to extend a monopoly over the leukemia drug Gleevec, finding that a group of buyers failed to show the pharma giant had no chance of winning its case....
Law360 is on it, so you are, too.
A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.
A Law360 subscription includes features such as
- Daily newsletters
- Expert analysis
- Mobile app
- Advanced search
- Judge information
- Real-time alerts
- 450K+ searchable archived articles
And more!
Experience Law360 today with a free 7-day trial.